Story
Haaretz · Israel
← Back to your feed

FDA approves pancreatic cancer device that extends survival from Israeli-founded Novocure

Study shows statistically significant survival gain – 16.2 months versus 14.16 – in what Novocure says is the first new treatment in decades for locally advanced pancreatic cancer

Read at Haaretz

Join the conversation

Discuss the story with the TraceFeed community.

No comments yet. Be the first to add a perspective.

Make it part of your feed.

Sign up or log in to continue.